Pacific Biosciences of California, Inc. provided revenue guidance for the full year 2022. As a result of macroeconomic factors discussed above, the company now expected 2022 revenue to be in the range of $138 million to $145 million.
Pacific Biosciences of California, Inc.
Equities
PACB
US69404D1081
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | -3.61% | -7.43% | -80.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-80.94% | 509M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.43% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- PACB Stock
- News Pacific Biosciences of California, Inc.
- Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022